BOTOX®, Allergan — Competitive Intelligence Brief

BOTOX®, Allergan (BOTOX®, Allergan) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Botulinum toxin type A. Area: Neurology, Dermatology, Ophthalmology.

phase 3 Botulinum toxin type A SNARE proteins (specifically SNAP-25) Neurology, Dermatology, Ophthalmology Small molecule

Target snapshot

BOTOX®, Allergan (BOTOX®, Allergan) — Assistance Publique - Hôpitaux de Paris. BOTOX blocks the release of acetylcholine at the neuromuscular junction by cleaving SNARE proteins, causing temporary paralysis of muscles.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
BOTOX®, Allergan TARGET	BOTOX®, Allergan	Assistance Publique - Hôpitaux de Paris	phase 3	Botulinum toxin type A	SNARE proteins (specifically SNAP-25)
Botox Cosmetic™	Botox Cosmetic™	Carruthers Dermatology Centre	marketed	Botulinum toxin type A	SNAP-25 (synaptosome-associated protein of 25 kDa)
NT 201	NT 201	Merz Aesthetics GmbH	marketed	Botulinum toxin type A	SNARE complex (acetylcholine release machinery)
powder BoNT-A (BOTOX/Vistabel)	powder BoNT-A (BOTOX/Vistabel)	Galderma R&D	marketed	Neurotoxin; botulinum toxin type A	SNAP-25 (synaptosome-associated protein of 25 kDa)
OnabotulinumtoxinA 100 UNT [Botox]	OnabotulinumtoxinA 100 UNT [Botox]	Women and Infants Hospital of Rhode Island	marketed	Neurotoxin; botulinum toxin type A	SNAP-25 (synaptosome-associated protein of 25 kDa)
incabotulinumtoxinA	incabotulinumtoxinA	Multiple Sclerosis Center of Northeastern New York	marketed	Botulinum toxin type A	SNARE complex (synaptobrevin/VAMP)
Intradetrusor Botox Injections	Intradetrusor Botox Injections	The Methodist Hospital Research Institute	marketed	Neurotoxin; botulinum toxin type A	SNARE complex (synaptosomal-associated protein); acetylcholine release machinery

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Botulinum toxin type A class)

1. Merz North America, Inc. · 2 drugs in this class
2. Department of Medical Services Ministry of Public Health of Thailand · 2 drugs in this class
3. Brigitte Schürch · 1 drug in this class
4. Carruthers Dermatology Centre · 1 drug in this class
5. Galderma R&D · 1 drug in this class
6. Huons Co., Ltd. · 1 drug in this class
7. Innovaderm Research Inc. · 1 drug in this class
8. Lupo Center for Aesthetic and General Dermatology · 1 drug in this class
9. Merz Aesthetics GmbH · 1 drug in this class
10. Multiple Sclerosis Center of Northeastern New York · 1 drug in this class